| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 11% | +38% | $694,720,745 | +$237,235,847 | 8,928,574 | +52% | FMR LLC | 31 Dec 2025 |
| BAKER BROS. ADVISORS LP | 11% | +14% | $551,236,913 | +$127,711,627 | 8,676,797 | +30% | Baker Bros. Advisors LP | 09 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 8.5% | $436,311,906 | 6,867,809 | BVF PARTNERS L P/IL | 11 Dec 2025 | |||
| VANGUARD GROUP INC | 8% | $173,996,098 | 5,231,392 | The Vanguard Group | 31 Mar 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.1% | $288,530,046 | 5,097,704 | T. Rowe Price Associates, Inc. | 30 Sep 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 5.5% | -28% | $322,541,273 | -$70,102,666 | 4,412,933 | -18% | Wellington Management Group LLP | 31 Dec 2025 |
| BlackRock, Inc. | 5.4% | $165,983,856 | 3,803,227 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Dec 2025, 250 institutional investors reported holding 89,832,595 shares of Kymera Therapeutics, Inc. - Common Stock (KYMR). This represents 112% of the company’s total 80,235,145 outstanding shares.
The largest institutional shareholders of Kymera Therapeutics, Inc. - Common Stock (KYMR) together control 93% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 11% | 8,928,574 | +52% | 0.04% | $694,732,353 |
| BAKER BROS. ADVISORS LP | 11% | 8,657,242 | +30% | 3.9% | $673,620,000 |
| Avoro Capital Advisors LLC | 9.3% | 7,474,747 | +18% | 5.7% | $581,610,064 |
| VANGUARD GROUP INC | 7.8% | 6,267,644 | +16% | 0.01% | $487,685,380 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.7% | 6,159,335 | +21% | 0.05% | $479,258,000 |
| BVF INC/IL | 6.9% | 5,502,710 | 0% | 14% | $428,165,865 |
| BlackRock, Inc. | 6.2% | 5,004,095 | +15% | 0.01% | $389,368,651 |
| Atlas Venture Life Science Advisors, LLC | 5.8% | 4,659,874 | -4.8% | 42% | $362,584,796 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.5% | 4,412,933 | -15% | 0.06% | $343,370,317 |
| Siren, L.L.C. | 4.1% | 3,286,830 | -4.1% | 7.6% | $255,748,242 |
| STATE STREET CORP | 2.8% | 2,209,837 | +9.4% | 0.01% | $171,947,417 |
| Capital Research Global Investors | 1.9% | 1,560,791 | +24% | 0.02% | $121,445,148 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,417,389 | +11% | 0.01% | $110,306,963 |
| Driehaus Capital Management LLC | 1.3% | 1,069,238 | +14% | 0.57% | $83,197,409 |
| ALLIANCEBERNSTEIN L.P. | 1.2% | 952,065 | +1852% | 0.02% | $74,080,178 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.1% | 912,498 | +5.6% | 0.02% | $71,001,470 |
| Merck & Co., Inc. | 0.96% | 772,165 | 0% | 22% | $60,082,159 |
| FEDERATED HERMES, INC. | 0.95% | 763,920 | +37% | 0.1% | $59,440,615 |
| Holocene Advisors, LP | 0.95% | 761,209 | -9.4% | 0.12% | $59,229,672 |
| Commodore Capital LP | 0.93% | 750,000 | 0% | 3.9% | $58,357,500 |
| GOLDMAN SACHS GROUP INC | 0.92% | 740,306 | +4.1% | 0.01% | $57,603,210 |
| UBS Group AG | 0.92% | 737,032 | +14% | 0.01% | $57,348,460 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 0.79% | 635,957 | +23% | 0.53% | $49,483,814 |
| T. Rowe Price Investment Management, Inc. | 0.78% | 629,745 | +3% | 0.03% | $49,001,000 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.78% | 626,430 | -2.8% | 0.76% | $48,742,648 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 89,832,595 | $6,990,212,625 | +$715,582,353 | $77.81 | 250 |
| 2025 Q3 | 80,869,485 | $4,577,075,616 | +$137,544,867 | $56.60 | 208 |
| 2025 Q2 | 78,801,021 | $3,438,754,240 | +$270,821,262 | $43.64 | 208 |
| 2025 Q1 | 72,808,716 | $1,995,263,098 | +$5,348,226 | $27.37 | 171 |
| 2024 Q4 | 71,721,890 | $2,885,022,540 | +$14,409,751 | $40.23 | 177 |
| 2024 Q3 | 69,051,239 | $3,268,392,680 | +$183,360 | $47.33 | 174 |
| 2024 Q2 | 67,390,465 | $2,011,640,213 | +$5,551,590 | $29.85 | 153 |
| 2024 Q1 | 67,207,302 | $2,701,742,064 | +$296,832,171 | $40.20 | 161 |
| 2023 Q4 | 60,455,852 | $1,539,280,108 | +$89,020,891 | $25.46 | 134 |
| 2023 Q3 | 57,350,132 | $797,188,696 | -$18,249,775 | $13.90 | 120 |
| 2023 Q2 | 58,230,116 | $1,338,678,295 | +$29,100,921 | $22.99 | 124 |
| 2023 Q1 | 56,859,649 | $1,683,467,091 | +$23,131,891 | $29.63 | 123 |
| 2022 Q4 | 56,195,243 | $1,402,708,961 | +$98,529,765 | $24.96 | 116 |
| 2022 Q3 | 52,859,306 | $1,150,805,258 | +$29,150,428 | $21.77 | 119 |
| 2022 Q2 | 49,442,050 | $973,574,555 | +$16,502,218 | $19.69 | 99 |
| 2022 Q1 | 45,688,568 | $1,933,296,396 | +$62,437,636 | $42.32 | 124 |
| 2021 Q4 | 43,015,870 | $2,729,867,438 | +$128,644,677 | $63.49 | 123 |
| 2021 Q3 | 34,637,185 | $2,035,073,191 | +$491,859,746 | $58.74 | 115 |
| 2021 Q2 | 26,479,657 | $1,284,263,574 | +$188,105,374 | $48.50 | 109 |
| 2021 Q1 | 22,191,421 | $862,345,865 | +$92,686,286 | $38.86 | 94 |
| 2020 Q4 | 20,299,967 | $1,247,002,136 | +$53,009,741 | $62.00 | 74 |
| 2020 Q3 | 16,828,031 | $542,529,000 | +$542,529,000 | $32.31 | 51 |